Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in moderate to severe ulcerative colitis
NCT02589665Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Dec 2015; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02589665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589665.